Who are Dopram's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chirocain, Mentax, PERHEXILINE, Bupivacaine Hydrochloride And Epinephrine, Bupivacaine Hydrochloride And Epinephrine, DIPHENIDOL HYDROCHLORIDE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/doxapram.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Dopram — Competitive Intelligence Brief

Dopram (DOXAPRAM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Respiratory Stimulant. Area: Neuroscience.

marketed Respiratory Stimulant Cytochrome P450 2D6 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Dopram (DOXAPRAM) — Hikma.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dopram TARGET	DOXAPRAM	Hikma	marketed	Respiratory Stimulant	Cytochrome P450 2D6	1965-01-01
Chirocain	LEVOBUPIVACAINE	Purdue Pharma Lp	marketed	levobupivacaine	Cytochrome P450 2D6	1999-01-01
Mentax	BUTENAFINE	Bayer	marketed	Benzylamine Antifungal	Cytochrome P450 2D6	1996-01-01
PERHEXILINE	PERHEXILINE		marketed	perhexiline	Carnitine O-palmitoyltransferase 1, liver isoform, Carnitine O-palmitoyltransferase 2, mitochondrial, Cytochrome P450 2D6	1974-01-01
Bupivacaine Hydrochloride And Epinephrine	Bupivacaine Hydrochloride	Pfizer	marketed	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	BUPIVACAINE	Innocoll	marketed	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
DIPHENIDOL HYDROCHLORIDE	DIPHENIDOL HYDROCHLORIDE		marketed	Anticholinergic	5-hydroxytryptamine receptor 2A, Cytochrome P450 2D6, D(2) dopamine receptor	1967-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Respiratory Stimulant class)

Hikma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dopram — Competitive Intelligence Brief. https://druglandscape.com/ci/doxapram. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab